K_Na1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons.

"Declaration of Competing Interest T.S.G. received consulting fees from Biogen. J.A.K. received research funding from Pfizer, Praxis, Ovid and Takeda, received consulting fees from Neurocycle Therapeutics, and received royalty income from GW Pharmaceuticals, Novartis, Stoke Therapeutics, StrideBio, Pfizer, Lund-beck, Bright Minds Biosciences, Xenon Pharmaceuticals, Noema Pharma, and Encoded Genomics. A.L.G. received research funding from Tevard Biosciences and Praxis Precision Medicines, and received consulting fees from Neurocrine Biosciences."

"Acknowledgments and funding sources. This work was supported by NIH grants NS104237 (TSG) and NS108874 (ALG, JAK), a research grant from the Child Neurology Foundation and Pediatric Epilepsy Research Foundation (TSG), a gift from the Davee Foundation (ALG), and the Northwestern Transgenic and Targeted Mutagenesis Laboratory. CRediT authorship contribution statement: Tracy S. Gertler: Conceptualization, Methodology, Formal analysis, Writing – original draft, Funding acquisition. Suraj Cherian: Methodology. Jean-Marc DeKeyser: Conceptualization, Methodology. Jennifer A. Kearney: Supervision, Writing – review & editing. Alfred L. George: Supervision, Writing – review & editing, Funding acquisition."